Results 201 to 210 of about 249,987 (395)

Application of real options in carbon capture and storage literature: Valuation techniques and research hotspots.

Science of the Total Environment, 2021
Casper Boongaling Agaton
semanticscholar   +1 more source

Optimal DCE design for modelling nonlinear time preferences in EQ-5D-5L valuation studies: exploration of data from Denmark and Peru. [PDF]

Health Qual Life Outcomes
Yu A, Street D, Jonker M, Bour S, Mulhern B, Augustovski F, Jensen C, Gudex C, Jensen M, Tejada R, Norman R, Viney R, Stolk E.   +12 more
europepmc   +1 more source

Comprehensive omics‐based classification system in adult patients with B‐cell acute lymphoblastic leukemia

Molecular Oncology, EarlyView.
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song, Ting Liu, Qishan Hao, Qiuyun Fang, Xiaoyuan Gong, Yan Li, Zheng Tian, Hui Wei, Min Wang, Jianxiang Wang, Tao Cheng, Yingchang Mi   +11 more
wiley   +1 more source

PMD5 VALUATION OF NEW DRUG APPLICATIONS OF PHARMACEUTICAL COMPANIES USING COMPOUND OPTION MODELS

, 2002
Danny Cassimon, PJ Engelen, Liesbeth Thomassen, Martine Van Wouwe   +3 more
openalex   +1 more source

The Sequential Compound Option Pricing with Random Interest Rate and Application to Project Valuation [PDF]

, 2006
Meng-Yu Lee, Fang Bo Yeh, An‐Pin Chen
openalex   +1 more source

Feedback from an avatar facilitates risk-taking by modulating the amygdala response to feedback uncertainty. [PDF]

PLoS Biol
Tanaka T, Haruno M.
europepmc   +1 more source

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab

Molecular Oncology, EarlyView.
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton, Russell W. Madison, Candice Francheska B. Tambaoan, Funda Meric‐Bernstam, Christopher J. Sweeney, Razelle Kurzrock, Howard A. Burris III, David R. Spigel, Hanna Tukachinsky, Jason Hughes, Julia Malato, Bongin Yoo, Tania Szado, Cheryl Schwab, Lincoln W. Pasquina, Amaya Gasco, Katja Schulze, Claire F. Friedman   +17 more
wiley   +1 more source

Evaluation of options for presenting health-states from PROMIS® item banks for valuation exercises

Quality of Life Research, 2018
J. Hanmer, D. Cella, D. Feeny, Baruch Fischhoff, R. Hays, R. Hess, P. Pilkonis, D. Revicki, M. Roberts, J. Tsevat, Lan Yu   +10 more
semanticscholar   +1 more source

Proactive Deprescribing Among Older Adults With Polypharmacy: Barriers and Enablers. [PDF]

Ann Fam Med
Ie K, Machino R, Albert SM, Tomita S, Ohashi H, Motohashi I, Otsuki T, Ohira Y, Okuse C.   +8 more
europepmc   +1 more source

Dose‐dependent induction of epithelial‐mesenchymal transition in 3D melanoma models by non‐thermal plasma treatment

Molecular Oncology, EarlyView.
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop, Edgar Cardenas De La Hoz, Hanne Verswyvel, Joey De Backer, Ho Wa Lau, Angela Privat‐Maldonado, Wim Vanden Berghe, Steve Vanlanduit, Evelien Smits, Annemie Bogaerts, Abraham Lin   +10 more
wiley   +1 more source